InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

Closed (no longer recruiting)Last updated: 20 February 2024

DYNAMIC-Pancreas: This Phase II/III trial is trying to determine whether a genetic test called “circulating tumour DNA” is an effective way to decide the specific type and duration of chemotherapy patients with localised pancreatic cancer should receive post-surgeryCirculating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study

Clinical summary


All participants in this study will have blood drawn during week 4 and week 8 post-surgery for circulating tumour DNA analysis. They will then be randomly allocated to one of two treatment groups, where the choice of chemotherapy regimen will be made prior to randomisation. Patients are eligible to join this trial if they are at least 18 years old, have undergone curative surgery for localised pancreatic cancer and have been recommended adjuvant chemotherapy


This trial is treating patients with pancreatic cancer.


Upper gastrointestinal tract Cancers Upper gastrointestinal tract





Trial Acronym


More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Walter and Eliza Hall Institute

Scientific Title

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study



 1. Subjects who have undergone complete macroscopic resection for adenocarcinoma of the pancreas (R0 or R1 resection) with “curative” intent.
2. A representative tumour sample is available for molecular testing within 6 weeks after surgery.
3. Subjects is fit for adjuvant chemotherapy.
4. Subject has ECOG performance status 0-2.
5. Subject is to attend for administration of adjuvant therapy.
6. Subject is accessible for follow up.
7. No evidence of malignant ascites, liver metastasis, spread to other distant abdominal organs, peritoneal metastasis, spread to extra-abdominal organs - Subject to have had a CT chest/ abdomen/ pelvis scan within 12 weeks prior to randomisation.
8. Fully informed written consent given


1. History of another primary cancer within the last 3 years, with the exception of non-melanomatous skin cancer and carcinoma in situ of the cervix.
2. Patient has inadequate organ function:
a. Moderate/severe renal impairment (GFR<30 ml/min), as calculated by the Cockcroft and Gault equation
b. Absolute neutrophil count <1.0x109/L
c. Platelet count <75x109/L
d. Haemoglobin <80 g/L
e. Aspartate aminotransferase/Alanine aminotransferase >2.5 x upper limit of normal
3. Patient has a medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol.
4. Patient has TNM stage IV disease.
5. Patient has R2 resection status.
6. Patient has clinically significant cardiovascular disease - i.e. active or <12 months since e.g. cerebrovascular accident, myocardial infarction, unstable angina, New York Heart Association grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, uncontrolled hypertension.


  • You have had a certain type of treatment or surgical procedure.


  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Closed hospitals

Completed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.


Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.